Tacrine Treatment IND Plan: 'Never Anything like It'

By Starr, Cynthia | Drug Topics, August 19, 1991 | Go to article overview

Tacrine Treatment IND Plan: 'Never Anything like It'


Starr, Cynthia, Drug Topics


Late last month, the Food & Drug Administration and Warner-Lambert Co. were occupying opposite ends of a wobbly seesaw. The fate of a compound that has been expected to become the first available drug for the treatment of Alzheimer's disease depends on the riders' ability to strike a balance.

An agent called tacrine or Cognex (also known as tetrahydroaminoacridine or THA) provides the fulcrum upon which the two sides are teetering. The drug candidate is designed to boost levels of acetylcholine, a neurotransmitter known to be deficient in Alzheimer's patients.

This past March, members of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted that the company's efficacy data did not yet warrant approval of the drug. At a second meeting in July, the committee held firm to that original stance. However, the eight-member voting panel was then asked to consider whether W-L should have a Treatment IND.

Try again: "The majority of the group, as I recall, said they thought the company should do another efficacy trial--a controlled efficacy trial at a higher dose of 120 mg," FDA spokeswoman Faye Peterson told Drug Topics. Patients had previously been treated with 40- and 80-mg doses per day of tacrine.

As for the Treatment IND, Peterson said, the panel was "a little split." Because the drug demonstrated a potential for liver damage when given at higher doses in earlier trials, the company would have to closely monitor patients if W-L were given permission for a Treatment IND, she added.

Most of the experts, Peterson went on, agreed that if the company could fully enroll an efficacy trial and get it under way, it could also receive a limited Treatment IND. The safety data culled from patients receiving the drug outside of the controlled study could be used in the application for marketing approval.

"We hadn't sought to do another (efficacy) trial," noted Peter Wolf, W-L manager of media relations. Instead, he said, the drugmaker was hoping that making tacrine available to a large number of patients through a Treatment IND would allow researchers to gather more information confirming its safety.

Reversible effect: The clinicians who have studied the drug believe the elevations that occur in liver enzymes are manageable and reversible, Wolf said. "We're not saying you don't need to be concerned. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Tacrine Treatment IND Plan: 'Never Anything like It'
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.